VEGF binding to the VEGF receptor induces phosphorylation of tyrosine kinase residues of the intracellular domain. Ephrin-B2 colocalizes in the membrane of endothelial cells in blood and lymphatic ...

a phenomenon that may be related to the increased expression of the VEGF receptors in ischemic tissues. It will also be important to determine whether overexpression of VEGF in ischemic myocardium ...

The HER family receptors form a signaling network that contributes to cancer progression. Angiogenesis plays a major role in cancer and VEGF-targeted agents have been shown to be useful in ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

The following is a summary of “Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives,” published in the December ...

Health Canada has granted market authorisation to Takeda Canada for FRUZAQLA (fruquintinib) capsules to treat adults with ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

“We are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but preliminary efficacy data as the study progresses,” said Dr. Huma Qamar, Chief ...

ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in ...